|
1）Vincent AM, Callaghan BC, Smith AL, et al. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011; 7: 573-83
|
|
|
|
2）The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86
|
|
|
|
|
|
3）Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006; 29: 340-4
|
|
|
|
|
|
4）Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.Diabetes Res Clin Pract. 1995; 28: 103-17
|
|
|
|
|
|
5）Vincent AM, McLean LL, Backus C, et al. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J. 2005; 19: 638-40
|
|
|
|
|
|
6）Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001; 24: 1448-53
|
|
|
|
|
|
7）Mohseni S. Hypoglycaemic neuropathy in diabetic BB/Wor rats treated with insulin implants affects ventral root axons but not dorsal root axons. Acta Neuropathol. 2000; 100: 415-20
|
|
|
|
|
|
8）Ozaki K, Sano T, Tsuji N, et al. Insulin-induced hypoglycemic peripheral motor neuropathy in spontaneously diabetic WBN/Kob rats. Comp Med. 2010; 60: 282-7
|
|
|
|
|
|
9）Kamiya H, Nakamura J, Hamada Y, et al. Polyol pathway and protein kinase C activity of rat Schwannoma cells. Diabetes Metab Res Rev. 2003; 19: 131-9
|
|
|
|
|
|
10）Kasuya Y, Nakamura J, Hamada Y, et al. An aldose reductase inhibitor prevents the glucose-induced increase in PDGF-beta receptor in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1999; 261: 853-8
|
|
|
|
|
|
11）Hotta N, Kawamori R, Atsumi Y, et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med. 2008; 25: 818-25
|
|
|
|
|
|
12）Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes. 1999; 48: 2090-5
|
|
|
|
|
|
13）Casellini CM, Barlow PM, Rice AL, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007; 30: 896-902
|
|
|
|
|
|
14）Toth C, Rong LL, Yang C, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes. 2008; 57: 1002-17
|
|
|
|
|
|
15）Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets. 2008; 9: 60-7
|
|
|
|
|
|
16）Li F, Szabo C, Pacher P, et al. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia. 2004; 47: 710-7
|
|
|
|
|
|
17）Tutuncu NB, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care. 1998; 21: 1915-8
|
|
|
|
|
|
18）Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004; 21: 114-21
|
|
|
|
|
|
19）Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest. 2001; 107: 1083-92
|
|
|
|
|
|
20）Kato N, Nemoto K, Nakanishi K, et al. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes. 2005; 54: 846-54
|
|
|
|
|
|
21）Nakae M, Kamiya H, Naruse K, et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes. 2006; 55: 1470-7
|
|
|
|
|
|
22）Naruse K, Sato J, Funakubo M, et al. Transplan-tation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in diabetic neuropathy. PLoS One. 2011; 6: e27458
|
|
|
|
|
|
23）Shibata T, Naruse K, Kamiya H, et al. Transplan-tation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008; 57: 3099-107
|
|
|
|
|
|
24）Naruse K, Hamada Y, Nakashima E, et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes. 2005; 54: 1823-8
|
|
|
|
|
|
25）Ropper AH, Gorson KC, Gooch CL, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol. 2009; 65: 386-93
|
|
|
|
|
|
26）Tomlinson DR, Fernyhough P, Diemel LT, et al. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes. 1997; 46 Suppl 2: S43-9
|
|
|
|
|
|
27）Karamoysoyli E, Burnand RC, Tomlinson DR, et al. Neuritin mediates nerve growth factor-induced axonal regeneration and is deficient in experimental diabetic neuropathy. Diabetes. 2008; 57: 181-9
|
|
|
|
|
|
28）Mizisin AP, Vu Y, Shuff M, et al. Ciliary neuro-trophic factor improves nerve conduction and ameliorates regeneration deficits in diabetic rats. Diabetes. 2004; 53: 1807-12
|
|
|
|
|
|
29）Kamiya H, Zhang W, Ekberg K, et al. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes. 2006; 55: 3581-7
|
|
|
|
|
|
30）Ekberg K, Brismar T, Johansson BL, et al. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes. 2003; 52: 536-41
|
|
|
|
|
|
31）Himeno T, Kamiya H, Naruse K, et al. Beneficial effects of exendin-4 on experimental polyneuro-pathy in diabetic mice. Diabetes. 2011; 60: 2397-406
|
|
|
|
|
|
32）Liu WJ, Jin HY, Lee KA, et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol. 2011; 164: 1410-20
|
|
|
|
|
|
33）Kan M, Guo G, Singh B, et al. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. J Neuropathol Exp Neurol. 2012; 71: 494-510
|
|
|
|
|
|
34）Jin HY, Liu WJ, Park JH, et al. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res. 2009; 40: 536-44
|
|
|
|
|